MATRIX METALLOPROTEASE (MMP) TARGETED AGENTS FOR IMAGING AND THERAPY
The present invention provides compound conjugates of matrix metalloprotease inhibitors and linked metal chelators which are useful for imaging solid tumors and treating and diagnosing certain types of diseases such as cancer.
1 . A compound conjugate comprising a matrix metalloprotease inhibitor (MMPi) portion and a linked metal chelator portion.
2 . The conjugate of claim 1 , wherein the MMPi is linked to the metal chelator portion by a bifunctional linker.
3 . The conjugate of claim 2 , wherein the bifunctional linker has the following structure
wherein A 1 indicates the point of attachment to the MMPi portion; and
A 2 indicates the point of attachment to the metal chelator portion.
4 . The conjugate of claim 1 , having the following structure:
wherein R 1 is selected from the group consisting of O and S;
wherein R 2 is selected from the group consisting of pyridyl and phenyl;
wherein when R 2 is phenyl, said phenyl at R 2 is optionally substituted with 1 to 5 substituents selected from the group consisting of OH, OCH 3 , OCF 3 and CH 3 ; and
wherein R 3 is the linked metal chelator portion.
5 . The conjugate of claim 4 , wherein R 3 is selected from the group consisting of
and
wherein the wavy line indicates the point of attachment to the remainder of the conjugate.
6 . The conjugate of claim 4 , having the following structure:
wherein R 4 is selected from the group consisting of
and
wherein the wavy line indicates the point of attachment at R 4 .
7 . The conjugate of claim 4 , having a structure selected from the group consisting of
8 . The conjugate of claim 4 , having a structure selected from the group consisting of
9 . The conjugate of claim 1 , and further comprising a radionuclide.
10 . The conjugate of claim 9 , wherein said radionuclide is selected from the group consisting of 225 Ac, 72 As, 211 At, 11 B, 128 Ba, 212 Bi, 75 Br, 77 Br, 14 C, 109 Cd, 62 Cu, 64 Cu, 67 Cu, 18 F, 67 Ga, 68 Ga, 3 H, 123 I, 125 I, 130 I, 131 I, 111 In, 177 Lu, 13 N, 15 O, 32 P, 33 P, 212 Pb, 103 Pd, 186 re, 188 Re, 47 Sc, 153 Sm, 89 Sr, 99m Tc, 88 Y and 90 Y.
11 . The conjugate of claim 9 , wherein said radionuclide is selected from the group consisting of 111 In and 99m Tc.
12 . The conjugate of claim 1 , and further comprising a lanthanide.
13 . The conjugate of claim 1 , and further comprising a lipid, a liposome, a micelle, a lipid-coated bubble, or a block copolymer micelle.
14 . The conjugate of claim 13 , wherein said lipid is a phospholipid, glycolipid, sphingolipid, or cholesterol.
15 . The conjugate of claim 1 , and further comprising a stealth agent.
16 . The conjugate of claim 15 , wherein said stealth agent is poly(ethylene glycol).
17 . A pharmaceutical composition comprising a conjugate of claim 1 .
18 . A method of diagnosing the presence of solid tumors in a patient, the method comprising the following steps:
administering a compound conjugate comprising a matrix metalloprotease inhibitor (MMPi) portion and a linked metal chelator portion to a patient;
acquiring a contrast image of the administered conjugate, or fragment thereof, in the patient;
analyzing said contrast image to determine the concentration of MMP enzymes; and;
diagnosing the presence of solid tumors based on said determination of the concentration of MMP enzymes;
wherein a locally high concentration of MMP enzymes indicates a diagnosis of solid tumors.
19 . The method of claim 18 , wherein the solid tumors are associated with a disease or condition selected from the group consisting of cancer, carcinoma, sarcoma, leukemia, lymphoma, myeloma, central nervous system cancer, solid tumors, and mixed tumors.
20 . A method for treating a patient having solid tumors, the method comprising:
administering a compound conjugate comprising a matrix metalloprotease inhibitor (MMPi) portion and a linked metal chelator portion to a patient having solid tumors;
thereby treating a patient having solid tumors.